Live Analyst Rating Changes 23771 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Jason Zemansky
BofA

Jason Zemansky

Wall Street Analyst
★★★☆☆
#1372
on 13Foresight · ranked by our own returns
49%
Success Rate
+5.7%
Average Return
36 of 73 calls profitable · +3.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 49% of Jason Zemansky's ratings turned a profit when each position was held for 1 year — averaging +5.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

124 Buy 59 Hold 13 Sell
Jason's Stock Coverage 22 ratings · 2026-08-13
Company Date Position Consensus Price Target 1-Yr Return vs S&P 500
KROS
Keros Therapeutics
Aug 11, 2026 HOLD Strong Buy
+119.7% avg upside
21 analysts
$17.00
52.46% Upside
+0.0% ·
TYRA
Tyra Bioscience
Aug 11, 2026 BUY Strong Buy
+76.0% avg upside
17 analysts
$39.00
55.21% Upside
· ·
LYEL
Lyell Immunopharma
Aug 11, 2026 SELL Strong Buy
+94.5% avg upside
12 analysts
$12.00
15.14% Downside
+1.1% ·
BBIO
BridgeBio Pharma
Aug 11, 2026 BUY Strong Buy
+12.8% avg upside
34 analysts
$104.00
24.35% Upside
+0.0% ·
RCUS
Arcus Biosciences
Aug 11, 2026 HOLD Strong Buy
+23.2% avg upside
20 analysts
$29.00
0.51% Upside
-0.6% ·
INSM
Insmed
Aug 07, 2026 BUY Strong Buy
+33.7% avg upside
37 analysts
$214.00
61.90% Upside
-1.7% ·
LGND
Ligand Pharma
Aug 07, 2026 BUY Strong Buy
-6.6% avg upside
15 analysts
-1.4% ·
CYTK
Cytokinetics
Aug 06, 2026 HOLD Strong Buy
+17.8% avg upside
36 analysts
$85.00
12.36% Upside
-7.5% ·
BMRN
BioMarin Pharmaceutical
Aug 06, 2026 BUY Strong Buy
+35.2% avg upside
52 analysts
$86.00
22.48% Upside
+14.3% ·
TVTX
Travere Therapeutics
Aug 05, 2026 BUY Strong Buy
-8.9% avg upside
22 analysts
$71.00
14.51% Upside
-0.6% ·
SNDX
Syndax Pharmaceuticals
Aug 05, 2026 BUY Strong Buy
+75.4% avg upside
27 analysts
$26.00
31.58% Upside
-2.2% ·
RCKT
Rocket Pharmaceuticals
Aug 03, 2026 BUY Buy
+384.4% avg upside
29 analysts
$10.00
193.16% Upside
+5.9% ·
MDGL
Madrigal Pharmaceuticals
Jul 30, 2026 HOLD Strong Buy
-6.4% avg upside
33 analysts
$543.00
1.17% Upside
+8.7% ·
BIIB
Biogen
Jul 29, 2026 HOLD Strong Buy
+21.4% avg upside
52 analysts
$219.00
5.10% Upside
-0.2% ·
KURA
Kura Oncology
Jul 27, 2026 BUY Strong Buy
+161.3% avg upside
26 analysts
$30.00
205.75% Upside
-1.6% ·
IKT
Inhibikase Therapeutics
Jul 27, 2026 BUY Strong Buy
+148.2% avg upside
8 analysts
$6.00
149.06% Upside
+2.1% ·
ABOS
Acumen Pharmaceuticals
Jun 11, 2026 BUY Strong Buy
+222.9% avg upside
10 analysts
$8.00
219.92% Upside
+4.2% ·
EIKN
Eikon Therapeutics, Inc.
Jun 03, 2026 BUY Buy
+129.2% avg upside
5 analysts
$32.00
207.74% Upside
-1.5% ·
HOWL
Werewolf Therapeutics
Feb 17, 2026 BUY Strong Buy
+1706.1% avg upside
8 analysts
$7.00
1738.18% Upside
-40.9% ·
OKUR
OnKure Therapeutics
Mar 28, 2024 SELL Buy
+499.2% avg upside
13 analysts
$12.00
205.38% Upside
+73.1% ·
KLRS
Kalaris Therapeutics
Dec 26, 2023 SELL Buy
+220.0% avg upside
13 analysts
$1.00
74.88% Downside
+37.0% ·
QTTB
Q32 Bio
Nov 17, 2023 HOLD Buy
+288.0% avg upside
24 analysts
+226.9% ·
🔒 17 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Jason Zemansky — Frequently Asked Questions
How accurate are Jason Zemansky's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Jason's ratings were profitable over a one-year hold, with an average return of +5.8% per rating, or +3.1% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Jason ranked on 13Foresight?
Jason Zemansky is currently ranked #1372 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Jason cover?
Jason most recently has ratings on KROS, TYRA, LYEL, BBIO, RCUS, INSM, LGND, CYTK, BMRN, TVTX, SNDX, RCKT and 10 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.